Fortitude Family Office’s Castle Biosciences CSTL Stock Holding History

Fortitude Family Office’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24	Buy	+1	New	+$22	﹤0.01%	2234

Other funds holding CSTL

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

First Bank & Trust Brookings, South Dakota $680M AUM 25.36% 1-Year Est. Return

Counterpoint Mutual Funds San Diego, California $1.01B AUM 37.65% 1-Year Est. Return

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

Mirae Asset Global Investments

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Fortitude Family Office's CSTL Position: Q2 2026 in Review

Fortitude Family Office opened a new position in Castle Biosciences (CSTL) in Q2 2026: 1 share worth $24. The stake represents ﹤0.01% of the portfolio and ranks #2234 among its holdings.

23 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

Fortitude Family Office held 1 share of Castle Biosciences worth $24 as of Q2 2026.
Castle Biosciences was a new Fortitude Family Office position in Q2 2026.
Castle Biosciences made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #2234 holding.
23 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.